118 related articles for article (PubMed ID: 23632263)
1. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy.
Talekar M; Ganta S; Amiji M; Jamieson S; Kendall J; Denny WA; Garg S
Int J Pharm; 2013 Jun; 450(1-2):278-89. PubMed ID: 23632263
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of PIK75 nanosuspension, a phosphatidylinositol-3-kinase inhibitor.
Talekar M; Kendall J; Denny W; Jamieson S; Garg S
Eur J Pharm Sci; 2012 Dec; 47(5):824-33. PubMed ID: 23069617
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo.
Tang XJ; Fu YH; Meng QH; Li LM; Ying XY; Han M; He QJ; Yang B; Zeng S; Hu YZ; Sheng XX; Gao JQ
Int J Pharm; 2013 Nov; 456(1):243-50. PubMed ID: 23928148
[TBL] [Abstract][Full Text] [Related]
4. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.
Wang Y; Liu Z; Zhang D; Gao X; Zhang X; Duan C; Jia L; Feng F; Huang Y; Shen Y; Zhang Q
Colloids Surf B Biointerfaces; 2011 Apr; 83(2):189-97. PubMed ID: 21176876
[TBL] [Abstract][Full Text] [Related]
5. Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor.
Danhier F; Ucakar B; Vanderhaegen ML; Brewster ME; Arien T; Préat V
Eur J Pharm Biopharm; 2014 Sep; 88(1):252-60. PubMed ID: 24859391
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use.
Lee SE; Bairstow SF; Werling JO; Chaubal MV; Lin L; Murphy MA; DiOrio JP; Gass J; Rabinow B; Wang X; Zhang Y; Yang Z; Hoffman RM
Pharm Dev Technol; 2014 Jun; 19(4):438-53. PubMed ID: 23617261
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells.
Talekar M; Ganta S; Singh A; Amiji M; Kendall J; Denny WA; Garg S
Pharm Res; 2012 Oct; 29(10):2874-86. PubMed ID: 22653667
[TBL] [Abstract][Full Text] [Related]
8. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
9. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.
Saxena V; Naguib Y; Hussain MD
Colloids Surf B Biointerfaces; 2012 Jun; 94():274-80. PubMed ID: 22377218
[TBL] [Abstract][Full Text] [Related]
10. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
[TBL] [Abstract][Full Text] [Related]
11. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
[TBL] [Abstract][Full Text] [Related]
12. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
[TBL] [Abstract][Full Text] [Related]
13. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition.
Zheng Z; Amran SI; Thompson PE; Jennings IG
Mol Pharmacol; 2011 Oct; 80(4):657-64. PubMed ID: 21778304
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHX) based nanoparticles for targeted cancer therapy.
Kılıçay E; Demirbilek M; Türk M; Güven E; Hazer B; Denkbas EB
Eur J Pharm Sci; 2011 Oct; 44(3):310-20. PubMed ID: 21884788
[TBL] [Abstract][Full Text] [Related]
15. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
16. Nanosuspension for parenteral delivery of a p-terphenyl derivative: preparation, characteristics and pharmacokinetic studies.
Tian X; Li H; Zhang D; Liu G; Jia L; Zheng D; Shen J; Shen Y; Zhang Q
Colloids Surf B Biointerfaces; 2013 Aug; 108():29-33. PubMed ID: 23528604
[TBL] [Abstract][Full Text] [Related]
17. In vitro-in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps.
Hill A; Geissler S; Meyring M; Hecht S; Weigandt M; Mäder K
Int J Pharm; 2013 Jul; 451(1-2):57-66. PubMed ID: 23628403
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity.
Wang Y; Ma Y; Zheng Y; Song J; Yang X; Bi C; Zhang D; Zhang Q
Int J Pharm; 2013 Jan; 441(1-2):728-35. PubMed ID: 23089583
[TBL] [Abstract][Full Text] [Related]
19. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Wang L; Liu Z; Liu D; Liu C; Juan Z; Zhang N
Int J Pharm; 2011 Jul; 413(1-2):194-201. PubMed ID: 21540085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
